Cardizem La Patent Expiration

Cardizem La is a drug owned by Bausch Health Us Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 25, 2021. Details of Cardizem La's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6923984 Cushioning wax beads for making solid shaped articles
Feb, 2021

(3 years ago)

Expired
US7108866 Chronotherapeutic diltiazem formulations and the administration thereof
Dec, 2019

(4 years ago)

Expired
US5529791 Extended release form of diltiazem
Jun, 2013

(11 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cardizem La's patents.

Given below is the list of recent legal activities going on the following patents of Cardizem La.

Activity Date Patent Number
Patent litigations
Recordation of Patent Grant Mailed 02 Aug, 2005 US6923984 (Litigated)
Patent Issue Date Used in PTA Calculation 02 Aug, 2005 US6923984 (Litigated)
Issue Notification Mailed 13 Jul, 2005 US6923984 (Litigated)
Receipt into Pubs 09 Jun, 2005 US6923984 (Litigated)
Dispatch to FDC 08 Jun, 2005 US6923984 (Litigated)
Application Is Considered Ready for Issue 08 Jun, 2005 US6923984 (Litigated)
Receipt into Pubs 07 Jun, 2005 US6923984 (Litigated)
Workflow - File Sent to Contractor 11 Apr, 2005 US6923984 (Litigated)
Issue Fee Payment Received 23 Mar, 2005 US6923984 (Litigated)
Issue Fee Payment Verified 23 Mar, 2005 US6923984 (Litigated)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Cardizem La is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cardizem La's family patents as well as insights into ongoing legal events on those patents.

Cardizem La's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Cardizem La's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 25, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Cardizem La Generics:

Diltiazem Hydrochloride is the generic name for the brand Cardizem La. 35 different companies have already filed for the generic of Cardizem La, with Actavis Labs Fl Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cardizem La's generic

How can I launch a generic of Cardizem La before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Cardizem La's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Cardizem La's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Cardizem La -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
120 mg, 180 mg, 240 mg, 300 mg and 360 mg 30 Aug, 2005 1 15 Mar, 2010 25 Jun, 2013 Deferred
420 mg 25 Apr, 2005 1 15 Mar, 2010 25 Jun, 2013 Deferred

Alternative Brands for Cardizem La

Cardizem La which is used for managing high blood pressure and chest pain., has several other brand drugs in the same treatment category and using the same active ingredient (Diltiazem Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch
Cardizem Cd

(uses Diltiazem Hydrochloride)

used for treating hypertension and angina pectoris.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Diltiazem Hydrochloride. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Bausch
Tiazac
Biovail
Diltiazem Hydrochloride


Apart from brand drugs containing the same ingredient, some generics have also been filed for Diltiazem Hydrochloride, Cardizem La's active ingredient. Check the complete list of approved generic manufacturers for Cardizem La





About Cardizem La

Cardizem La is a drug owned by Bausch Health Us Llc. It is used for managing high blood pressure and chest pain. Cardizem La uses Diltiazem Hydrochloride as an active ingredient. Cardizem La was launched by Bausch in 2003.

Approval Date:

Cardizem La was approved by FDA for market use on 06 February, 2003.

Active Ingredient:

Cardizem La uses Diltiazem Hydrochloride as the active ingredient. Check out other Drugs and Companies using Diltiazem Hydrochloride ingredient

Treatment:

Cardizem La is used for managing high blood pressure and chest pain.

Dosage:

Cardizem La is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
300MG TABLET, EXTENDED RELEASE Prescription ORAL
120MG TABLET, EXTENDED RELEASE Prescription ORAL
360MG TABLET, EXTENDED RELEASE Prescription ORAL
180MG TABLET, EXTENDED RELEASE Prescription ORAL
420MG TABLET, EXTENDED RELEASE Prescription ORAL
240MG TABLET, EXTENDED RELEASE Prescription ORAL